Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
D. Dube, P. Tiwari & P. Kaur. (2016) The hunt for antimitotic agents: an overview of structure-based design strategies. Expert Opinion on Drug Discovery 11:6, pages 579-597.
Read now
Read now
Tao Wang, Mian-Bin Wu, Jian-Ping Lin & Li-Rong Yang. (2015) Quantitative structure–activity relationship: promising advances in drug discovery platforms. Expert Opinion on Drug Discovery 10:12, pages 1283-1300.
Read now
Read now
Gwenola Manic, Florine Obrist, Antonella Sistigu & Ilio Vitale. (2015) Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy. Molecular & Cellular Oncology 2:4.
Read now
Read now
Enaksha R. Wickremsinhe, Scott M. Hynes, Margo D. Palmieri, Malcolm I. Mitchell, Trent L. Abraham, Jessica Fayer Rehmel, Emilie Chana, Lorenz M. Jost & Kenneth C. Cassidy. (2014) Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica 44:9, pages 827-841.
Read now
Read now
João FS Carvalho & Roland Kanaar. (2014) Targeting homologous recombination-mediated DNA repair in cancer. Expert Opinion on Therapeutic Targets 18:4, pages 427-458.
Read now
Read now
Articles from other publishers (46)
Ruoxi Wang, Yating Sun, Chunshuang Li, Yaoyao Xue & Xueqing Ba. (2023) Targeting the DNA Damage Response for Cancer Therapy. International Journal of Molecular Sciences 24:21, pages 15907.
Crossref
Crossref
Ian Collins. 2023. The Handbook of Medicinal Chemistry. The Handbook of Medicinal Chemistry
847
872
.
Salman Ahmed, Waqas Alam, Michael Aschner, Khalaf F. Alsharif, Ashraf Albrakati, Luciano Saso & Haroon Khan. (2022) Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy. Biomedicine & Pharmacotherapy 155, pages 113797.
Crossref
Crossref
Siyao Deng, Tijana Vlatkovic, Moying Li, Tianzuo Zhan, Marlon R. Veldwijk & Carsten Herskind. (2022) Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. Cancers 14:19, pages 4874.
Crossref
Crossref
Liesbeth Everix, Shankari Nair, Cathryn H. S. Driver, Ingeborg Goethals, Mike M. Sathekge, Thomas Ebenhan, Charlot Vandevoorde & Julie Bolcaen. (2022) Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma. Cancers 14:7, pages 1821.
Crossref
Crossref
Stina George Fernandes, Prachi Shah & Ekta Khattar. (2022) Recent Advances in Therapeutic Application of DNA Damage Response Inhibitors
against Cancer. Anti-Cancer Agents in Medicinal Chemistry 22:3, pages 469-484.
Crossref
Crossref
Magdalena Staniszewska, Janette Iking, Katharina Lückerath, Boris Hadaschik, Ken Herrmann, Justin Ferdinandus & Wolfgang P. Fendler. (2021) Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. Nuclear Medicine and Biology 96-97, pages 101-111.
Crossref
Crossref
Joanna Zell, Francesco Rota Sperti, Sébastien Britton & David Monchaud. (2021) DNA folds threaten genetic stability and can be leveraged for chemotherapy. RSC Chemical Biology 2:1, pages 47-76.
Crossref
Crossref
Lulu Li, Alagamuthu Karthick Kumar, Zhigang Hu & Zhigang Guo. (2021) Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy. Current Medicinal Chemistry 28:5, pages 963-985.
Crossref
Crossref
Xingkai Du, Jian Li, Xiaojiao Luo, Rong Li, Feng Li, Yiwen Zhang, Jianyou Shi & Jun He. (2020) Structure-activity relationships of Wee1 inhibitors: A review. European Journal of Medicinal Chemistry 203, pages 112524.
Crossref
Crossref
Kornelia Czaja, Jacek Kujawski, Karol Kamel & Marek K. Bernard. (2020) Selected arylsulphonyl pyrazole derivatives as potential Chk1 kinase ligands—computational investigations. Journal of Molecular Modeling 26:6.
Crossref
Crossref
Jabeena Khazir, Bilal Ahmad Mir, Meeshu Pandita, Lynne Pilcher, Darren Riley & Gousia Chashoo. (2020) Design and synthesis of sulphonyl acetamide analogues of quinazoline as anticancer agents. Medicinal Chemistry Research 29:5, pages 916-925.
Crossref
Crossref
Akash Jori, Sheshagiri R. Dixit & Gurubasavraj V. Pujar. (2020) Synthesis and in vitro Cytotoxicity Study of Novel 4-Substituted
Quinazolines Encompassed with Thiazolidinone and Azetidinone. Asian Journal of Chemistry 32:10, pages 2617-2623.
Crossref
Crossref
Ina Patties, Sonja Kallendrusch, Lisa Böhme, Eva Kendzia, Henry Oppermann, Frank Gaunitz, Rolf-Dieter Kortmann & Annegret Glasow. (2019) The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Crossref
P. Meghana, Jain R. Sandeep Kumar, Telkar Sandeep, N. Prashanth & H. M. Kumaraswamy. (2019) Acetogenins as potential checkpoint-2 kinase inhibitors: an in silico analysis. Journal of Proteins and Proteomics 10:4, pages 299-311.
Crossref
Crossref
Pinakin Pandya, Alex Braiman & Noah Isakov. (2019) PICOT (GLRX3) is a positive regulator of stress-induced DNA-damage response. Cellular Signalling 62, pages 109340.
Crossref
Crossref
Lexian Tong, Pinrao Song, Kailong Jiang, Lei Xu, Tingting Jin, Peipei Wang, Xiaobei Hu, Sui Fang, Anhui Gao, Yubo Zhou, Tao Liu, Jia Li & Yongzhou Hu. (2019) Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies. European Journal of Medicinal Chemistry 173, pages 44-62.
Crossref
Crossref
Dolores Santa María, Rosa M. Claramunt, José Elguero, Miguel Carda, Eva Falomir & Celia Martín-Beltrán. (2019) New N,C-Diaryl-1,2,4-triazol-3-ones: Synthesis and Evaluation as Anticancer Agents. Medicinal Chemistry 15:4, pages 360-372.
Crossref
Crossref
Patrick G. Pilié, Chad Tang, Gordon B. Mills & Timothy A. Yap. (2018) State-of-the-art strategies for targeting the DNA damage response in cancer. Nature Reviews Clinical Oncology 16:2, pages 81-104.
Crossref
Crossref
Mohamed S. A. Elsayed, Jeffery J. Nielsen, Sungtae Park, Jeongho Park, Qingyang Liu, Chang H. Kim, Yves Pommier, Keli Agama, Philip S. Low & Mark Cushman. (2018)
Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[
c
]pyrrolo[2,3-
h
][1,6]naphthyridin-5-one (BPN) Series
. Journal of Medicinal Chemistry 61:23, pages 10440-10462.
Crossref
Crossref
Josep V. Forment & Mark J. O’Connor. (2018) Targeting the replication stress response in cancer. Pharmacology & Therapeutics 188, pages 155-167.
Crossref
Crossref
Shadia A. Galal, Sarah H.M. Khairat, Hamed I. Ali, Samia A. Shouman, Yasmin M. Attia, Mamdouh M. Ali, Abeer E. Mahmoud, Abeer H. Abdel-Halim, Amal A. Fyiad, Ashraf Tabll, Reem El-Shenawy, Yasmine S. El Abd, Raghda Ramdan & Hoda I. El Diwani. (2018) Part II: New candidates of pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors. European Journal of Medicinal Chemistry 144, pages 859-873.
Crossref
Crossref
Ian Collins & Michelle D. Garrett. 2018. Targeting the DNA Damage Response for Anti-Cancer Therapy. Targeting the DNA Damage Response for Anti-Cancer Therapy
241
276
.
Ana Alcaraz-Sanabria, Cristina Nieto-Jiménez, Verónica Corrales-Sánchez, Leticia Serrano-Oviedo, Fernando Andrés-Pretel, Juan Carlos Montero, Miguel Burgos, Juan Llopis, Eva María Galán-Moya, Atanasio Pandiella & Alberto Ocaña. (2017) Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer. Molecular Cancer Therapeutics 16:11, pages 2552-2562.
Crossref
Crossref
Ahmad A. Tarhini, Theofanis Floros, Hui-Min Lin, Yan Lin, Zahra Rahman, Madeeha Ashraf, Priyanka Vallabhaneni, Cindy Sander, Uma N.M. Rao, Monica Panelli, William F. LaFramboise & John M. Kirkwood. (2017) A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma. Melanoma Research 27:5, pages 429-438.
Crossref
Crossref
Beverly A. Teicher, Thomas Silvers, Michael Selby, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Ralph Parchment, Julia Krushkal, Dmitriy Sonkin, Larry Rubinstein, Joel Morris & David Evans. (2017) Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent. Cancer Medicine 6:8, pages 1952-1964.
Crossref
Crossref
Shadia A. Galal, Ahmed S. Abdelsamie, Samia A. Shouman, Yasmin M. Attia, Hamed I. Ali, Ashraf Tabll, Reem El-Shenawy, Yasmine S. El Abd, Mamdouh M. Ali, Abeer E. Mahmoud, Abeer H. Abdel-Halim, Amal A. Fyiad, Adel S. Girgis & Hoda I. El-Diwani. (2017) Part I: Design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs. European Journal of Medicinal Chemistry 134, pages 392-405.
Crossref
Crossref
Stuart Rundle, Alice Bradbury, Yvette Drew & Nicola Curtin. (2017) Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers 9:12, pages 41.
Crossref
Crossref
Cyril Ronco, Anthony R. Martin, Luc Demange & Rachid Benhida. (2017) ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells. MedChemComm 8:2, pages 295-319.
Crossref
Crossref
Jessica S. Brown, Brent O'Carrigan, Stephen P. Jackson & Timothy A. Yap. (2017) Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discovery 7:1, pages 20-37.
Crossref
Crossref
Ganiy Opeyemi Abdulrahman & N.J. Curtin. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
104
133
.
Sumit S. Chourasiya, Deepika Kathuria, Sampada S. Nikam, Ashok Ramakrishnan, Sadhika Khullar, Sanjay K. Mandal, Asit K. Chakraborti & Prasad V. Bharatam. (2016) Azine-Hydrazone Tautomerism of Guanylhydrazones: Evidence for the Preference Toward the Azine Tautomer. The Journal of Organic Chemistry 81:17, pages 7574-7583.
Crossref
Crossref
Daniel Markowitz, Caitlin Powell, Nhan L. Tran, Michael E. Berens, Timothy C. Ryken, Magimairajan Vanan, Lisa Rosen, Mingzhu He, Shan Sun, Marc Symons, Yousef Al-Abed & Rosamaria Ruggieri. (2016) Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma. Molecular Cancer Therapeutics 15:8, pages 1799-1808.
Crossref
Crossref
James D. Osborne, Thomas P. Matthews, Tatiana McHardy, Nicolas Proisy, Kwai-Ming J. Cheung, Michael Lainchbury, Nathan Brown, Michael I. Walton, Paul D. Eve, Katherine J. Boxall, Angela Hayes, Alan T. Henley, Melanie R. Valenti, Alexis K. De Haven Brandon, Gary Box, Yann Jamin, Simon P. Robinson, Isaac M. Westwood, Rob L. M. van Montfort, Philip M. LeonardMarieke B. A. C. LamersJohn C. ReaderG. Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Michelle D. Garrett & Ian Collins. (2016)
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (
R
)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
. Journal of Medicinal Chemistry 59:11, pages 5221-5237.
Crossref
Crossref
Marc A. Labroli, Michael P. Dwyer, Cory Poker, Kerry M. Keertikar, Randall Rossman & Timothy J. Guzi. (2016) A convergent preparation of the CHK1 inhibitor MK-8776 (SCH 900776). Tetrahedron Letters 57:24, pages 2601-2603.
Crossref
Crossref
Takahiro Takada, Soichi Tsutsumi, Ryo Takahashi, Katsuya Ohsone, Hironori Tatsuki, Toshinaga Suto, Toshihide Kato, Takaaki Fujii, Takehiko Yokobori & Hiroyuki Kuwano. (2016) KPNA2 over-expression is a potential marker of prognosis and therapeutic sensitivity in colorectal cancer patients. Journal of Surgical Oncology 113:2, pages 213-217.
Crossref
Crossref
P E Brennan. (2016) Deciphering the true antiproliferative target of an MK2 activation inhibitor in glioblastoma. Cell Death & Disease 7:1, pages e2069-e2069.
Crossref
Crossref
Mike I. Walton, Paul D. Eve, Angela Hayes, Alan T. Henley, Melanie R. Valenti, Alexis K. De Haven Brandon, Gary Box, Kathy J. Boxall, Matthew Tall, Karen Swales, Thomas P. Matthews, Tatiana McHardy, Michael Lainchbury, James Osborne, Jill E. Hunter, Neil D. Perkins, G. Wynne Aherne, John C. Reader, Florence I. Raynaud, Suzanne A. Eccles, Ian Collins & Michelle D. Garrett. (2015) The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma. Oncotarget 7:3, pages 2329-2342.
Crossref
Crossref
Lewis Gazzard, Karen Williams, Huifen Chen, Lorraine Axford, Elizabeth Blackwood, Brenda Burton, Kerry Chapman, Peter Crackett, Joy Drobnick, Charles Ellwood, Jennifer Epler, Michael Flagella, Emanuela Gancia, Matthew Gill, Simon Goodacre, Jason Halladay, Joanne Hewitt, Hazel Hunt, Samuel Kintz, Joseph Lyssikatos, Calum Macleod, Sarah Major, Guillaume Médard, Raman Narukulla, Judi Ramiscal, Stephen Schmidt, Eileen Seward, Christian Wiesmann, Ping Wu, Sharon Yee, Ivana Yen & Shiva Malek. (2015) Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1. Journal of Medicinal Chemistry 58:12, pages 5053-5074.
Crossref
Crossref
Nour Jamal Jaradat, Mohammad A. Khanfar, Maha Habash & Mutasem Omar Taha. (2015) Combining docking-based comparative intermolecular contacts analysis and k-nearest neighbor correlation for the discovery of new check point kinase 1 inhibitors. Journal of Computer-Aided Molecular Design 29:6, pages 561-581.
Crossref
Crossref
Carmen Avendaño & J. Carlos Menéndez. 2015. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs
391
491
.
Scott M. Hynes, Enaksha Wickremsinhe, Wei Zhang, Rodney Decker, Jennifer Ott, Jason Chandler & Malcolm Mitchell. (2015) Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients. Biopharmaceutics & Drug Disposition 36:1, pages 49-63.
Crossref
Crossref
L. Zannini, D. Delia & G. Buscemi. (2014) CHK2 kinase in the DNA damage response and beyond. Journal of Molecular Cell Biology 6:6, pages 442-457.
Crossref
Crossref
Pinrao Song, Peng Peng, Mengmeng Han, Xianchao Cao, Xiaodong Ma, Tao Liu, Yubo Zhou & Yongzhou Hu. (2014) Design, synthesis and biological evaluation of thienopyridinones as Chk1 inhibitors. Bioorganic & Medicinal Chemistry 22:17, pages 4882-4892.
Crossref
Crossref
Todd M. Pitts, S. Lindsey Davis, S. Gail Eckhardt & Erica L. Bradshaw-Pierce. (2014) Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors. Pharmacology & Therapeutics 142:2, pages 258-269.
Crossref
Crossref
Shin-Hwar Wu, Tzu-Yun Wu, Yung-Ting Hsiao, Ju-Hwa Lin, Shu-Chun Hsu, Te-Chun Hsia, Su-Tso Yang, Wu-Huei Hsu & Jing-Gung Chung. (2014) Bufalin Induces Cell Death in Human Lung Cancer Cells through Disruption of DNA Damage Response Pathways. The American Journal of Chinese Medicine 42:03, pages 729-742.
Crossref
Crossref